Long-term remission of corticosteroid-resistant Graves' orbitopathy after therapy with tocilizumab

Endokrynol Pol. 2024;75(1):117-118. doi: 10.5603/ep.97224.

Authors

Joanna Rymuza¹, Aleksander Kuś², Dorota Białas-Niedziela³, Monika Turczyńska³, Dariusz Kęcik³, Tomasz Bednarczuk²

Affiliations

¹ Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw, Poland. joanna.rymuza@wum.edu.pl.
² Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw, Poland.
³ Department of Ophthalmology, Medical University of Warsaw, Warsaw, Poland.

PMID: 38497401
DOI: 10.5603/ep.97224

Abstract

Not required for Clinical Vignettes.

Keywords: Graves’ orbitopathy; tocilizumab.

MeSH terms

Adrenal Cortex Hormones / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Graves Ophthalmopathy* / drug therapy
Humans

Substances

tocilizumab
Antibodies, Monoclonal, Humanized
Adrenal Cortex Hormones